材料,结构和药物释放之间的相关性Nexplanon®:以乙烯乙酸乙烯 (EVA) 为基础的长效植入物
Ziyue Zhong1, Angela Ren1, Nicholas Doluisio1
1The University of Texas at Austin, College of Pharmacy, Department of Molecular Pharmaceutics and Drug Delivery, Austin, TX, USA.
International journal of pharmaceutics
|July 16, 2025
概括
描述了Nexplanon®药物释放的特征,揭示了由超和驱动的两相释放特征,并受到耗尽区域和边界层的影响. 数学模型阐明了这些复杂的药物释放机制.
科学领域:
- 药理动力学和药物输送方法
- 生物材料科学 生物材料科学
- 数学建模的数学建模
背景情况:
- 尼克斯拉 (Nexplanon®) 是一种长效避孕植入物,其复杂的药物释放机制尚未完全理解.
- 传统的三年药物释放测试是耗时和劳动密集的.
- 描述Nexplanon®的材料,结构和药物释放对于优化其性能至关重要.
研究的目的:
- 描述Nexplanon®的材料,结构和药物释放情况.
- 阐明控制药物释放的关键物理现象,包括超和,耗尽区和未的边界层效应.
- 开发和验证用于预测Nexplanon®药物释放的数学模型.
主要方法:
- 关于Nexplanon®植入物的材料和结构特征.
- 从植入物皮肤和末端释放药物的独立研究.
- 数学建模以阐明药物释放现象.
- 对药物超和,耗尽区形成和未的边界层效应的分析.
主要成果:
- 尼克斯拉 (Nexplanon®) 具有双相药物释放特征:最初的突发释放 (前20天),随后持续释放.
- 爆发释放是由通过乙烯乙酸乙烯 (EVA) 膜的药物超和驱动的.
- 持续释放受到未的边界层效应和枯竭区形成的影响,导致释放率低于预测.
- 植入物末端的释放量高于预测,这是由于充满水的多孔枯竭区域中的药物透性.
结论:
- 了解Nexplanon®复杂的药物释放机制对于其有效使用至关重要.
- 数学建模为药物释放现象提供了宝贵的见解,有助于开发预测模型.
- 这些发现可以为未来的长效药物输送系统的设计提供信息,这些系统具有优化的释放概况.
相关概念视频
01:20Drug Product Performance: In Vitro–In Vivo Correlation
392
In pharmaceutical development, it's crucial to establish a predictive in vitro–in vivo correlation (IVIVC) for two or more formulations to gain a comprehensive understanding of release properties. IVIVC reduces the need for costly in vivo studies and facilitates the establishment of meaningful dissolution specifications with significant cost savings and decreased regulatory burden. Furthermore, a meaningful IVIVC should predict Cmax and AUC within 20%, aligning with FDA guidance while...
392
01:19Modified-Release Drug Delivery Systems: Rate-Programmed II
103
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
103
01:20Modified-Release Drug Delivery Systems: Influencing Factors
159
Modified-release drug delivery systems are designed to optimize the therapeutic effect of drugs by minimizing side effects, reducing the dosage required, and controlling drug release to align with pharmacokinetic and pharmacodynamic needs. The system depends on two key factors: the drug's release from the formulation and its movement through the body to the target site. Unlike conventional dosage forms, where absorption is the limiting step, the rate of drug release is the key determinant in...
159
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
225
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
225
01:11Oral Drug Delivery Systems: Delayed-Release Systems
180
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
180
01:21Intrauterine Drug Delivery Systems
150
Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
150